The skin remains an attractive area for drug delivery. The skin, however, often limits the ingress of drugs, because of its very low permeability. Much research, focusing on employing a variety of physical and chemical methods, aimed at reversibly altering skin permeability in favour of compounds, has been reported on. Of the many chemical approaches that exist, one comprises the use of vesicular carriers for delivering drugs into and possibly through the skin. This review offers an overview of various vesicles that have been investigated during dermal and transdermal drug delivery research in recent years, with special emphasis on a relatively new carrier, namely the Pheroid™. The progress made to date by our research group with regards to the use of the Pheroid™ as transdermal delivery vector, is also discussed in detail.
Introduction
Controlling the drug release and its site-specific delivery by carriers is not the only challenge in therapeutic research. Many physicochemical constraints of active pharmaceutical ingredients (APIs) negatively impact on their ability to cross biological membranes, therefore limiting their efficacy [1] . The development of vesicular carriers has attracted considerable attention during the last two decades, and vesicles are sought to address the problems associated with targeted drug delivery. The ultimate goal of vesicular carriers is to produce therapeutically efficient formulations for various clinical situations. For this reason, carriers are expected to meet a number of prerequisites, such as 1) biocompatibility and biodegradability, 2) high drug loading, 3) site-specific drug delivery to avoid any undesirable side effects, and 4) the controlled release of the drug at the target site [2] . To date, a limited number of vesicular carriers have successfully achieved these requirements, and have been further tested for dermal and transdermal, parenteral, ocular, oral and pulmonary drug delivery. This review aims at discussing the vesicular carriers intended for dermal and transdermal drug delivery. To augment this, the application and mechanisms of action of various vesicular carriers in dermal and transdermal drug delivery are discussed first. Afterwards, the versatility and effectiveness of the novel patented Pheroid™ delivery system in delivering APIs through the dermal route is extensively discussed. The Pheroid is a colloidal delivery system comprised of essential and plant fatty acids emulsified in nitrous oxide saturated water [3] . Next, an overview of the progress made to date by our research group in this domain will be given. Finally, this review concludes with a summary.
Skin as a route of drug delivery
The skin, having a large surface area of approximately 2 m 2 [4] , has increasingly been considered as a potential drug delivery alternative. Topical application of drugs for local targeting of various skin disease conditions is known as dermal drug delivery, while transdermal drug delivery comprises the systemic transport of drugs through the skin. Drug delivery through the skin offers various advantages, including avoidance of hepatic metabolism, the elimination of gastrointestinal disturbances associated with oral delivery, non-invasive needless drug delivery, whilst a constant and controlled release of the drug can be achieved [5, 6] .
The skin, being a protective layer of the body, offers a barrier to most compounds requiring delivery into and through it [7] . The outermost layer of the skin, the stratum corneum (SC), represents the effective barrier that limits the ingress of chemicals. The structure of the SC has classically been described as a brick and mortar model [8] , with the corneocytes acting as the bricks and the intercellular lipid lamellae as the mortar. It has been suggested that the highly organised intercellular lipids comprise the main component of the barrier properties of the SC [9, 10] . Main pathways of drug permeation include transepidermal-, transappendageal-and transfollicular routes ( Fig.  1 ) [11] . The transepidermal pathway consists of intercellular and intracellular routes.
The intercellular route is considered a continuous, but tortuous pathway through the intercellular lipids. Contrary, the transcellular pathway starts through the keratinocytes and then crosses through the intercellular lipids. To pass through the transcellular pathway, drugs need to successively partition and diffuse through the keratinocytes and intercellular lipid layers [12] . The transappendageal and transfollicular routes play a minor role in the transport of compounds across the skin, because both of these pathways cover only 0.1% of the total skin surface area [13] . Fig. 1 : Representation of a cross-section of the skin and various possible routes of drug penetration [14] .
Application of materials on the skin surface creates a concentration gradient, which drives molecules into and across the skin through the diffusion process. This concentration gradient directly depends upon skin permeability and the application area on the skin surface. When molecules diffuse across the skin under free molecular motion, skin permeability is proportional to the diffusivity and the partition coefficient of the permeant [7] , as calculated by the following equation. The diffusion path length also influences the penetration ability of a permeant.
Generally, the effective solute transport across the skin depends upon the relative extent of the trans-barrier water and permeant flows [15] . Any solute being administered epicutaneously is therefore pushed across the skin, under the influence of concentration gradient. In the process, the solute attracts water towards the skin surface, whilst maintaining its inward thrust through the intrinsic osmotic pressure difference. Conversely, for a perfectly permeable solute, transport across the skin barrier does not require an osmotically driven trans-barrier water flow [16] .
The application area on the skin surface also dictates how much of a permeant can pass through. Since the amount of permeant that can pass through the skin also depends upon the permeant solubility in the skin, limited solubility can restrict the maximum achievable flux. This can be countered by either changing the application area, or by enhancing skin permeability through the use of chemical enhancers, or through physical energy means. So far, various physical and chemical methods have been investigated in an attempt to compromise the SC barrier to enable the effective transport of compounds across the skin [17] . These approaches are discussed in detail in various recent publications [18] [19] [20] [21] .
Vesicles for dermal and transdermal drug delivery
Vesicles are spherical, often nano-sized, lipid-based carriers, within which a drug can be encapsulated in either the aqueous core, or inside of the lipid bilayer. Usually, these vesicles are formulated using physiological lipids, such as phospholipids and cholesterol, and thus, they are well tolerated, non-toxic and biodegradable. Various vesicular carriers that are used in dermal and transdermal drug delivery are discussed next. These vesicles include liposomes, niosomes, transfersomes, ethosomes, and a relatively new type of vesicle, namely Pheroid.
Liposomes

Structure, methods of preparation and properties
Liposomes are phospholipid-based mono-or multi-concentric bilayer vesicles that contain a central aqueous compartment, and are generally in the size range of 20 nm to several micrometres [22] . Phospholipids are amphiphilic and spontaneously form bilayers upon hydration. Liposomes can be categorised into various classes, based upon their lipid bilayers, size and method of preparation. Examples are small unilamellar vesicles (SUV), large unilamellar vesicles (LUV), multilamellar vesicles (MUV), oligolamellar vesicles (OUV) and multi-vesicular vesicles (MVV) [23, 24] .
Liposomes can be prepared through a variety of methods, depending upon the target size and their properties. Various formulation methods of liposomes have recently been reviewed by other authors [25] . Generally, all methods of preparation and subsequent drug loading involve four basic steps [25] , namely: Liposomes are the most common and the most studied nano-carriers for drug delivery purposes, because of their unique characteristics [26] . They are biocompatible, biodegradable, non-toxic, and have an excellent capability of targeting the desired site of action, while also having easily tunable surface properties.
Mechanisms of action
Various mechanisms of action of liposomes have been proposed and are reported in detail in previous publications [27, 28] . The subject of liposomes, however, remains controversial with regards to their ability to enhance topical and transdermal drug delivery. A brief description of the reported mechanisms is discussed in the next few paragraphs.
Firstly, the free drug mechanism, as proposed by Ganesan et al. [29] , comprises that the drug penetrates the skin after its release from the vesicles on the skin surface. Enhancement of the topical delivery of estradiol, when employing the proposed mechanism was, however, found negligible during another study [30] .
Secondly, Kato et al. [31] described the penetration enhancement properties of lecithin-based liposomes by compromising the skin barrier properties. Similar findings are also reported by other researchers [30, [32] [33] [34] . Contrary, other studies also report on the negative effects that liposomes have on drug penetration through the skin [35] [36] [37] .
Thirdly, liposomes may possibly interact with the skin and fuse with the lipid bilayers to become part of the membrane [38] , and therefore enhance drug partitioning in the SC [30, 39] .
Finally, early reports by Mezei and Gulasekharam [40, 41] propose that the intact vesicle itself may penetrate the skin. Similarly, Foldvari et al. [42] suggest that intact liposomes could reach the dermis. Lasch et al. [43] further suggest that only intact SUVs are able to penetrate the SC. Contrary, Du Plessis et al. [44] report that relatively larger sized liposomes were found to have enhanced the drug deposition in the skin, compared to smaller sized vesicles. Such enhanced drug deposition was believed to be indicative of the intact vesicles not having penetrated the skin.
In summary, it still remains enigmatic as to what extent liposomes are able to penetrate the skin. From the mixed reports it appears that small intact liposomes may penetrate the SC to some extent, but not beyond it. The penetration enhancing effect also relies upon the composition of the liposomes.
Liposomes as dermal and transdermal delivery vectors
Mezei and Gulasekharam [40] had initiated research on liposomes as a potential drug carrier in skin. Their work showed that triamcinolone loaded liposome-based lotion formulations could increase the drug deposition in the skin layers by three-to four-fold, with a minimal increase in systemic drug concentrations, compared with standard drug solutions. Later, Touituo et al. [45] also demonstrated a higher skin deposition of caffeine from liposomal formulations. These initial studies promised the suitability of liposomes as topical delivery vectors for localised effects. Some studies also highlighted that liposomes could target the appendages (hair follicles and associated sebaceous glands). Investigation of the deposition of gamma interferon into human, hairless rat and hamster skin revealed the highest accumulation in the hamster skin, having the highest follicular density among the three skin models [46] . Subsequently, the follicular pathway was proposed as a route of drug deposition into the skin. Contrary, El Maghraby et al. [47] demonstrated that the follicular pathway in transdermal delivery from liposomes played a negligible role. The discrepancies among the reported outcomes could translate into different approaches being adopted in formulating liposomes, for example the use of different lipid components in the vesicles. Surprisingly, some earlier reports had also claimed transdermal permeation of drugs from liposomes. The research outcomes by Ganesan et al. [29] on rat skin and by Artmann et al. [48] on piglet skin clearly demonstrated enhanced percutaneous absorption of test drugs and antibodies, respectively. The reason behind these conflicting outcomes may have resulted from different mechanisms operating concurrently, such as the drug having diffused percutaneously from the localised reservoir, thus eliciting transdermal permeation.
Niosomes
Structure, method of preparation and properties
Niosomes are surfactant vesicles that are similar to liposomes in structure and properties. They consist of non-ionic surfactants, either with or without cholesterol or lipids, and are cost effective, compared with conventional liposomes [49] . Niosomes share the same general preparation methodology like other lipid vesicles, and can be prepared as uni-and multi-lamellar vesicles. Several other methods have, however, also been reported [49] . Proniosome is another term routinely used for the dried, nonionic surfactant vesicles, coated with a water-soluble carrier such as sorbitol and maltodextrin, which are converted into niosomes upon hydration. Proniosomes address the instability disadvantages associated with niosomes, such as aggregation, fusion and leaking, and can enhance the entrapment efficiency of drugs [50] .
Mechanisms of action
The mechanism of niosome action generally resembles that of the liposomes, as reported by several researchers [32, [51] [52] [53] .
Niosomes as dermal and transdermal delivery vectors
In recent years, niosomes have been extensively studied as dermal and transdermal delivery carriers for various drugs. In this context, Fang et al. [54] compared the skin permeation of enoxacin from niosomes and conventional liposomes. Results revealed superior permeation and skin retention of drugs from niosomal formulations, compared with their liposomal counterparts. Such enhanced skin permeation was attributed to the penetration enhancement effect of the niosomal vesicles, coupled with their fusion with the skin lipids. In another study, Agarwal et al. [55] demonstrated that the antipsoriatic activity of dithranol loaded niosomes was superior to that of the conventional cream formulation, and a two-fold increase in flux was recorded across mouse abdominal skin, compared with the control. Lakshmi et al. [56] also studied the antipsoriatic activity of methotrexate loaded niosomes. The study protocol was double-blind placebo controlled, involving healthy human volunteers and psoriatic patients. The antipsoriatic activity of the niosomal formulation was three times higher than that of the marketed gel formulation. These studies confirmed superior dermal targeting of niosomes, compared with the conventional formulations. A recent ex vivo permeation study of tenoxicam loaded proniosomes revealed higher flux rates, compared with the carbopol gel formulation [57] . This enhancement was believed to have been as a result of the fusion of vesicles with the skin surface and the subsequent transfer of the tenoxicam directly on the skin surface for faster permeation.
Although all of these studies had revealed an enhanced permeation of the drugs being loaded into niosomes, the extent to which these niosomes could penetrate the skin could not be established. Junyaprasert et al. studied the in vitro permeation of ellagic acid (EA) from niosomes made of Span 60 and Tween 60 [58] . They applied confocal laser scanning microscopy (CLSM) to investigate the skin distribution of these vesicles. On analysing the receptor media, EA was found only when a niosomal formulation was used, compared with EA solutions. This meant that EA was able to cross the skin only when niosomes had been used. The CLSM photographs (data not shown) revealed deeper distribution of EA from niosomes, compared with using the solution formulations, which confirmed the enhanced penetration of niosomes across the human skin.
In summary, non-ionic surfactant vesicles have shown promise in targeting deeper skin layers, and could possibly be employed as dermal and transdermal delivery vectors.
Transfersomes
Structure, method of preparation and properties
Transfersomes comprise of a unique class of liposomal vesicles that are highly elastic and ultra-deformable. These vesicles had been introduced by Cevc and Blume in 1992 [59] and were claimed to have penetrated deep into the skin layers, thus reaching the systemic circulation. Transfersomes are composed of a mixture of phospholipids and surfactants. Phospholipids form bilayers, while elasticity is provided by a high mobility surfactant or an edge activator. Commonly used surfactants include bile salts (sodium cholate, sodium deoxycholate) and non-ionic surfactants (e.g. Span 60, Span 80, Tween 60, and Tween 80). Upon mechanical stress, the edge activators are displaced to relocate to zones with higher stress, whereas the amphipathic lipids form bilayers with smaller curvature. Such rearrangements are responsible for eliminating the membrane's elastic energy, resulting in the formation of highly deformable vesicles, with elasticities of more than five-fold that of the conventional liposomes [60] .
Mechanism of action
Transfersomes have the ability to squeeze into pores that are much smaller than the vesicle size. This property makes them interesting drug vectors for skin penetration. According to Cevc [16] , transfersomes should be applied under nonocclusive conditions, such that the osmotic gradient on the skin surface allows for them to penetrate deep into the viable epidermis, while maintaining their intactness.
Transfersomes as dermal and transdermal delivery vectors
The basic elastic properties of transfersomes have been exploited in delivering drugs topically and transdermally. Cevc et al. [61] report on the unfragmented penetration of fluorescence marked transfersomes across murine skin. They also demonstrated that the sizes of the vesicles had not changed during penetration across intact skin, which further confirmed that the elasticity of the vesicles had been sufficient for crossing the much smaller SC pores. In another study, Cevc and Blume had demonstrated a higher potency of hydrocortisone when entrapped in elastic vesicles, compared with traditional cream formulation that contained five-fold more of the drug [62] . They also showed a four-fold longer duration of action of dexamethasone when encapsulated in transfersome, compared with the commercial cream formulation. Transfersomes, therefore, demonstrated the ability to improve therapeutic benefits, arguably because of better targeting and higher drug deposition in the skin. Similar results were also reported by Trotta et al. [63] . They prepared transfersomes for topical targeting of methotrexate, using full thickness pig ear skin as model membrane. The elastic vesicles showed better permeation and higher skin retention, compared with aqueous solution and conventional liposomes. Other studies also showed successful transdermal delivery of insulin [64] , interferon and interleukin [65] from ultra-deformable vesicles.
In a very recent study, Zhang et al. [66] demonstrated the transdermal penetration of cinnamic acid loaded transfersomes across the skin of Sprague-Dawley rats. They reported a higher flux of cinnamic acid from transfersomes, compared with the conventional liposomes. More interestingly, in vivo dermal microdialysis investigations revealed a higher concentration of cinnamic acid retained in the skin by conventional liposomes (3.21 ± 0.25 μg/mL), compared with transfersomes (0.59 ± 0.02 μg/mL), suggesting that transfersomes had penetrated the skin and reached the systemic circulation.
In summary, transfersomes appear to have the ability to cross intact skin, and are the vesicles of choice for targeting deeper skin layers and for transdermal drug delivery.
Ethosomes
Structure, method of preparation and properties
Ethosomes are nano-sized soft vesicles, mainly composed of phospholipids with a high concentration of ethanol (20 -50%) and water. Their size is highly tunable and depends on the ethanol content in the formulation. The higher the ethanol content, the smaller the vesicle size. Ethosomes are patented nano-carriers, as reported by Professor Elka Touitou [67, 68] , and they are claimed to penetrate deeper skin layers, whilst being capable of even reaching the systemic circulation. Unlike liposomes, the phospholipids in ethosomes are less densely packed and fluidic, because of the high ethanol content, thus making these vesicles softer and the vesicular membrane highly permeable to cations [69] . The presence of high concentrations of ethanol can dramatically enhance the solubility of hydrophobic drugs in the ethosomes, and they are thus able to payload a higher amount of drugs to the target sites.
Mechanism of action
Ethosomes are known to be efficient permeation enhancers, owing to their ability to fluidise the SC lipids. The presence of ethanol not only makes the vesicles softer, but also disturbs the lipid organisation of the SC, thereby, exerting a penetration enhancement effect. These softer vesicles can then easily penetrate across the SC and may result in enhanced transdermal drug delivery [70] .
Ethosomes as dermal and transdermal delivery vectors
Ethosomes have been successfully used as vectors for dermal and transdermal drug delivery. Godin et al. [71] investigated the targeting of minoxidil loaded ethosomes of hair follicles of hairless rats in vivo. Results indicated that a higher amount of drug could be delivered to the pilosebaceous units in comparison with conventional liposomes. In another study, Horwitz et al. [72] loaded ethosomes with acyclovir to target herpetic infection in a double-blind, randomised clinical trial. The results showed quick improvement in the disease condition, using an ethosomal formulation, compared with a marketed cream product. This significantly improved pharmacodynamic profile endorsed ethosomes as potential dermal delivery vectors.
Touitou et al. also found enhanced transdermal delivery of testosterone from ethosomes, both in vitro and in vivo, compared with to marketed patch formulations [73] . Subsequently, Dayan and Touitou [74] compared ethosomes and conventional liposomes for the delivery of trihexyphenidyl HCl across nude mouse skin. The resultant flux of the drug from ethosomes was significantly higher than that from conventional liposomes and hydroalcoholic solutions. Skin retention of the drug was also higher for ethosomes, compared with liposomes and hydroalcoholic solutions.
Surface charge of such colloidal vesicles is an important determinant of interaction with the target site. Considering the net negative charge of the skin surface, Meng et al. [75] deliberately modified the ethosome surface charge, using a cationic surfactant, namely cetyltrimethylammonium bromide. These surfactant-modified ethosomes were loaded with testosterone propionate and subjected to in vitro and in vivo skin permeation. Results indicated a significantly higher drug flux across mouse skin, compared with conventional liposomes. The in vivo pharmacokinetic profiles in rats also revealed higher blood plasma levels of testosterone from the ethosomal formulations, compared with liposomes.
These reports emphasised the possibility of ethosomes being suitable for use in dermal and transdermal drug delivery.
Pheroid™
Structure, methods of preparation and properties
The novel Pheroid colloidal delivery system, formerly known as Emzaloid ® , comprises of stable, lipid-based, submicron-and micron sized structures, or vesicles, that are homogenously distributed within a dispersion medium [76] . These vesicles are liposome like structures, consisting of a hydrophilic core and a bilayer membrane [3] . Numerous registered patents on the Pheroid technology describe the use of the Pheroid delivery system in enhancing the efficacy and in promoting the absorption of biological, dermatological and oral medicines [76] . One of the advantages of the Pheroid system is that this stable structure (within a system) can be manipulated with regards to its function, morphology, structure and size [3, 76] . Several Pheroid types can be formulated to have diameters ranging between 200 nm and 2 µm, depending on the administration route, delivery rate, and the amount and size of the API [76] .
A Pheroid mainly comprises of ethylated and pegylated polyunsaturated fatty acids, which include the omega-3 and omega-6 fatty acids (excluding arachidonic acid) [76] . Slightly modified linolenic acid and linoleic acid, emulsified in nitrous oxide saturated water, are inherent components of the Pheroid and are present in all formulations [76, 77] . Numerous additional long chain unsaturated fatty acids can be added to support the unsaturated fatty acids, depending on the precise indication and pathology of the Pheroid [76] . The Pheroid is a skin-friendly carrier system, as the fatty acids present in Pheroid are oriented in the cis-formation, making it compatible with the fatty acids found in human cells. At present, all topical Pheroid formulations contain tocopherol, or tocopherol-based molecules, to serve as both an anti-oxidant and an emulsion stabiliser [76] . Fig. 2 offers a schematic representation of the general composition of the Pheroid.
The Pheroid has some features similar to other colloidal dosage forms. In general, the Pheroid contains a lipid bilayer, like the liposomes, although it does not contain phospholipids or cholesterol. A Pheroid is formed by a self-assembly process, comparable with that of low-energy emulsions and micro-emulsions. The Pheroid contains two liquid phases (such as emulsions), as well as a dispersed gas phase (i.e. nitrous oxide). The nitrous oxide is associated with the fatty acid dispersed phase and contributes towards the self-assembly process of the Pheroid, its stability, as well as the miscibility of the fatty acids in the dispersion medium. The Pheroid is a versatile carrier system, having some of the reservoir characteristics of polymeric microspheres and can also form natural depots, similar to macromolecular microspheres [76] . [76] . In contrast, the Pheroid contains no cholesterol in its lipid bilayer [3] and it is sterically stabilised by electro-chemical interaction, allowing for its highly elastic vesicular structure [76] . Another advantage of the Pheroid delivery system is that hydrophobic compounds can be entrapped within its elastic lipid membrane, whereas hydrophilic compounds can reside in the central hydrophilic aqueous core [3] . Fig. 2 indicates the phase in which either lipophilic or hydrophilic drugs would be incorporated into the Pheroid system.
Mechanism of action
It is believed that the fluidity of the Pheroid membrane plays a part in the dermal and transdermal delivery of APIs. However, the uptake of the Pheroid may also be influenced by the cell's mechanism of uptake, as well as by the formulation of the Pheroid. The mechanism by which the Pheroid is taken up by cells is hypothesised to be facilitated by the fatty acid membrane-binding proteins usually present within lipid rafts in the cell membrane. Thereafter, the Pheroid is either metabolised within the peroxisomes, or inside the cells' mitochondria (depending on the composition of the Pheroid), resulting in the release of the entrapped API [76] .
Pheroid as transdermal delivery vector
The Pheroid has proven a successful transdermal and dermal delivery vehicle of some compounds, but not for all the APIs and formulations tested. For the purpose of this review, the focus will only be on transdermal delivery and not on dermal delivery. Furthermore, the different studies performed are divided into two groups, i.e., enhanced or reduced transdermal delivery with the Pheroid.
Improved transdermal drug delivery with Pheroid
The Pheroid system had enhanced the transdermal delivery of certain APIs, of which selected physicochemical properties are summarised in Table 1 .
The permeation enhancement abilities of Emzaloid ® (now known as Pheroid™), compared to the heat separated epidermal layer of human abdominal skin were compared with two lamellar gel phase systems (referred to as commercial systems A and B), with the use of two APIs, i.e. 5-fluorouracil (5FU) (1.0% w/w) and idoxuridine (1.0% w/w). Compared with a control group (API dissolved in HPLC grade water), Emzaloid ® had the highest enhancement ratio (ER = 20.33) for 5FU, followed by commercial product B (ER = 5.00) and commercial product A (ER = 4.67). Emzaloid ® also had the highest enhancement ratio (ER = 3.50) for idoxuridine, compared with the control, followed by commercial product B (ER = 1.75) and commercial product A (ER = 1.31) [78] .
Further studies by Van Dyk [79] were performed by dissolving or entrapping 5FU (1.0% w/v) in either HPLC grade water (control), phosphate buffer solution (PBS, control), water-based Pheroid solution, or PBS-based Pheroid solution. It was found that the Pheroid delivery system had enhanced the transdermal penetration of 5FU over the heat separated epidermal layer of the skin (over 12 hours). The water-based Pheroid formulation was found to be far more superior in enhancing the average flux of 5FU (0.891 ± 1.577 µg/cm 2 .h) than the PBS-based Pheroid (0.412 ± 0.824 µg/cm 2 .h), followed by PBS and water with average flux values for 5FU of 0.122 ± 0.210 µg/cm 2 .h and 0.075 ± 0.103 µg/cm 2 .h, respectively. Additionally, it was concluded from this study that a 0.5% 5FU concentration in water-based Pheroid formulation could be used instead of a 1.0% concentration, since no statistically significant differences were found between a 1.0% and 0.5% formulation [79] .
Studies by Vermaas [80] , however, did not result in the same enhancement of the permeation of 5FU (at a concentration of 0.5% w/v) by the Pheroid delivery system in semi-solid formulations(refer to Section 3.5.3.2). As a result, more studies were performed to determine the effect of the Pheroid delivery system on the permeation of 5FU from lotions with different concentrations of this API. Different concentrations of 5FU (i.e. 0.5, 1.0, 2.0 and 4.0% w/w) lotions were formulated with and without the addition of Pheroid. The total amount of 5FU that had diffused over a period of 12 hours across dermatomed human abdominal skin (400 µm thickness) was the highest for the 4% w/w Pheroid lotion (57.60 μg/cm 2 ), followed by the 0.5% w/w Pheroid lotion (31.60 μg/cm 2 ), 2.0% w/w Pheroid lotion (28.50 μg/cm 2 ), 1.0% w/w Pheroid lotion (16.20 μg/cm 2 ), 4.0% w/w lotion (15.90 μg/cm 2 ), 1.0% w/w lotion (11.90 μg/cm 2 ), 2.0% w/w lotion (9.71 μg/cm 2 ) and finally the 0.5% w/w lotion (4.63 μg/cm 2 ). These outcomes indicated that, generally, higher total amounts of 5FU had diffused from the Pheroid lotions (with different concentrations of 5FU) than from those lotions without Pheroid [81] . The Pheroid delivery system was found to have improved the flux of the peptide drug, arginine vasopressin (150.0 µg/mL), compared with the passive control cells, in which the drug was dissolved in Hepes buffer, pH 5.5. The in vitro permeation profiles (across the epidermal layer of the skin) of arginine vasopressin showed a biphasic character, with most of the permeation having occurred during the first 2 hours of the study. These flux values obtained within the first 2 hours were higher for arginine vasopressin in Pheroid (0.495 ± 0.188 µg/cm 2 .h), than for arginine vasopressin in Hepes buffer (pH 5.5) (0.037 ± 0.065 µg/cm 2 .h). Flux values obtained for the 2 -12 hours' time interval showed a similar pattern, i.e. arginine vasopressin in Pheroid (0.038 ± 0.050 µg/cm 2 .h) had a higher flux than when arginine vasopressin had been dissolved in Hepes buffer (pH 5.5) (0.018 ± 0.028 µg/cm 2 .h). In further diffusion studies, bestatin HCl (300 µg/mL, a selective aminopeptidase inhibitor) was included in the donor solution to prevent the degradation of the active by skin enzymes, which in turn may have also had an enhancing effect on the permeation of arginine vasopressin. A comparison of the flux values obtained during the first 2 hours of the study showed that the flux obtained when arginine vasopressin and bestatin HCl had been dissolved in Pheroid was higher (0.218 ± 0.186 µg/cm 2 .h) than when arginine vasopressin and bestatin had been dissolved in Hepes buffer (pH 5.5) (0.158 ± 0.169 µg/cm 2 .h). The flux values obtained during the 2 -12 hours' time interval, however, showed that the flux values were higher when arginine vasopressin and bestatin had been dissolved in Hepes buffer (pH 5.5) (0.062 ± 0.063 µg/cm 2 .h), than when dissolved in Pheroid (0.058 ± 0.051 µg/cm 2 .h) [98] .
The Pheroid delivery system also proved to be advantageous to the transdermal delivery (across full thickness abdominal skin, only fat layer removed) of two other peptide drugs, i.e. tumour necrosis factor-alpha (TNF-α) and transforming growth factor-beta1 (TGF-β1). The effects of the Pheroid were compared with the outcomes of a study during which these actives had been dissolved in PBS (pH 7.4). The aminopeptidase inhibitor, bestatin HCl, was again added to prevent any skin related degradation. TNF-α and TGF-β1were entrapped within Pheroid vesicles at concentrations of 500.0 pg/mL and 1000.0 pg/mL, respectively. The average diffused concentration of TNF-α after 12 hours with Pheroid was 88.48 ± 0.98 pg/cm 2 , only slightly higher than the average concentration of 82.66 ± 1.44 pg/cm 2 obtained with PBS (pH 7.4). The average diffused concentration of TGF-β1 after 6 hours was much higher with Pheroid (302.44 pg/cm 2 ) than with PBS (pH 7.4) (148.28 pg/cm 2 ) [99] .
The Pheroid delivery system furthermore proved to be more effective in the delivery of two anti-tubercular drugs, i.e. isoniazid (INH) (5.0 mg/mL) and rifampicin (RH) (10.0 mg/mL), compared with the PBS (pH 5.5) control study outcomes. Permeation profiles obtained after in vitro diffusion studies across the epidermal layer of human abdominal skin for INH showed a biphasic character, whereas the permeation profiles for RH were triphasic. The average flux of INH during the 0 -2 hours interval was 0.290 ± 0.650 µg/cm 2 .h and 2.640 ± 2.310 µg/cm 2 .h for PBS (pH 5.5) and Pheroid, respectively. For the 2 -12 hours interval, the average INH flux was 0.300 ± 0.150 µg/cm 2 .h for PBS (pH 5.5) and 1.140 ± 0.890 µg/cm 2 .h for Pheroid. No flux was observed for RH in PBS (pH 5.5), whereas the average flux of RH with Pheroid was 1.870 ± 2.080 µg/cm 2 .h, 0.66 ± 0.90 µg/cm 2 .h and 0.230 ± 0.410 µg/cm 2 .h for the 0.0 -1.5 hours, 1.5 -4.0 hours and 4.0 -12.0 hours intervals, respectively [100] .
A preliminary study showed that the Pheroid delivery system had improved the transdermal diffusion of acyclovir (5.0% w/v), but not that of ketoconazole (2.0% w/v) (refer to Section 3.5.3.3), when Franz cell skin diffusion studies were conducted on the epidermal layer of human abdominal skin. The permeation profile of acyclovir showed a biphasic character. During the 0 -2 hours interval, the Pheroid delivery system had increased the average flux of acyclovir (ER of 1.12), compared with the PBS control. The flux of the Pheroid during the 2 -12 hours interval was 1.63 order higher than that of the control [101] .
Following the above mentioned study, acyclovir (5.0% w/w) and ketoconazole (2.0% w/w) were formulated into semi-solid products (creams and emulgels), with and without (control) the Pheroid delivery system. It was found that the Pheroid cream had the highest (2970.03 µg/cm 2 ) average cumulative amount of acyclovir that had permeated full-thickness human abdominal skin over a period of 12 hours, followed by the cream (2172.20 µg/cm 2 ), the emulgel (482.38 µg/cm 2 ) and the Pheroid emulgel (413.56 µg/cm 2 ). The concentrations of ketoconazole that had diffused through the skin after 12 hours had the following ranking order: Pheroid emulgel (447.55 µg/cm 2 ) ˃ cream (38.86 µg/cm 2 ) ˃ emulgel (25.68 µg/cm 2 ) ˃ Pheroid cream (0.00 µg/cm 2 ). From these results it was concluded that the Pheroid formulae had increased the transdermal permeation of these APIs, although the type of formulation (i.e. emulgel or cream) was also a determining factor [102] .
The transdermal delivery (across the epidermal layer of human abdominal skin) of two ionisable amide types of local anaesthetics (i.e. lidocaine HCl and prilocaine HCl, both at a concentration of 2.5% w/v) with the Pheroid was compared with a commercial cream. The vasoconstrictor, adrenaline, was added to the formulations in a concentration of 1:100 relative to the APIs to localise the anaesthetic effect. The permeation profiles obtained with the Pheroid vesicles showed a biphasic character, in which rapid permeation was observed during the first 2 hours, where after it plateaued between 3 -12 hours. The average flux of lidocaine HCl during the first 2 hours was higher for Pheroid (617.120 µg/cm 2 .h) than for the commercial product (73.810 µg/cm 2 .h). This was the same for prilocaine HCl, i.e. the flux for the Pheroid was 699.490 µg/cm 2 .h, compared with 53.930 µg/cm 2 .h for the commercial product. A comparison of the flux values obtained during the 3 -12 hours interval showed that Pheroid (106.420 µg/cm 2 .h) was still slightly superior to the commercial cream (99.430 µg/cm 2 .h) in improving the permeation of lidocaine HCl. Flux values for prilocaine HCl during this time interval was marginally higher for the Pheroid (118.890 µg/cm 2 .h) than for the commercial cream (101.500 µg/cm 2 .h). The addition of adrenaline to the formulations had no significant effect [103] .
In another study, it was found that the average amount per area of L-carnitine Ltartrate (2% w/v) that had diffused across full thickness human abdominal skin was 1.6 times better with the Pheroid after 8 hours, than with PBS (pH 7.4) [89] .
Creams containing 20.0% of azelaic acid (with and without Pheroid), as well as gels containing 15.0% of azelaic acid (with and without Pheroid) were formulated. A comparison of the 12 hours average cumulative concentrations (across full thickness abdominal skin) of azelaic acid showed that more azelaic acid (38.48 µg/cm 2 ) had diffused from the Pheroid creams than from the non-Pheroid creams (3.23 µg/cm 2 ). In contrast, the non-Pheroid gel formulations (24.51 µg/cm 2 ) showed better diffusion values than the Pheroid gels (11.03 µg/cm 2 ) [87] .
A study showed that zinc acetate (1.2%) was able to diffuse through full thickness abdominal skin from Pheroid and non-Pheroid creams and emulgels; although no flux values were obtained. Placebo formulations (without zinc) were also tested to determine any possible endogenous zinc diffusion. When comparing the average concentration of zinc that had permeated through the skin after 6 hours, it was found that the Pheroid emulgels (0.12 μg/cm 2 ) and non-Pheroid emulgels (0.05 μg/cm 2 ) had transferred insignificant zinc concentrations transdermally, compared with the placebos. In contrast, the Pheroid creams (9.23 μg/cm 2 ) and non-Pheroid creams (8.71 μg/cm 2 ) had delivered significant amounts of zinc transdermally. These results showed that the incorporation of Pheroid into the formulations had a positive effect on the diffusion of zinc across the skin [97] .
Alpha-lipoic acid (1.0% w/w) was used as the active in a Pheroid cream, a Pheroid gel, and a non-Pheroid cream and gel. It was determined that the active did not penetrate through full thickness skin from the non-Pheroid cream, nor the gel over a 12 hour period. The results, however, indicated that the Pheroid had improved alphalipoic acid's transdermal delivery across the skin. For the Pheroid cream a steady state flux of 58.010 ± 6.630 µg/cm 2 .h was observed after the first 2 hours of the diffusion study, where after the cumulative concentration of the active remained the same for the subsequent 3 -6 hours interval. This suggested that the entire amount of alpha-lipoic acid had diffused through the skin from the Pheroid cream. The Pheroid gel had an average flux of 22.180 ± 3.330 µg/cm 2 .h during the 4 -12 hours interval [86] .
Reduced or no enhancement in transdermal drug delivery with Pheroid
In this section those studies during which the Pheroid had either shown no effect or a reduced effect on the transdermal delivery of certain APIs are discussed. The physicochemical properties of these APIs are summarised in Table 2 . Those APIs that had shown improved transdermal delivery during initial studies are listed in Table 1 only. Previous results (discussed above, [78, 79] ) showed that Pheroid had improved the transdermal penetration of 5FU. Subsequently, six formulations, each containing 0.5% of 5FU were prepared, i.e. a non-Pheroid cream, -emulgel and -lotion, and a Pheroid cream, -emulgel and -lotion. A 0.5% 5FU water solution, a 0.5% 5FU Pheroid solution and a 5% 5FU commercial product (ointment) were also tested. A direct comparison with the commercial product was made by testing two solutions, i.e. a 5.0% 5FU non-Pheroid and a 5.0% 5FU Pheroid solution during Franz cell skin diffusion studies. The water solution containing the 5.0% 5FU had achieved the highest average cumulative concentration (11.158 µg/cm 2 ) after 12 hours across full thickness human abdominal skin. The comparison of the 0.5% formulations and solutions showed that the emulgel had achieved the highest average cumulative concentration (10.86 µg/cm 2 ), followed by the Pheroid lotion (10.01 µg/cm 2 ), the 0.5% water solution (9.63 µg/cm 2 ), the lotion (9.06 µg/cm 2 ), the Pheroid emulgel (8.97 µg/cm 2 ), the cream (7.59 µg/cm 2 ), the Pheroid cream (7.07 µg/cm 2 ) and the 0.5% Pheroid solution (6.18 µg/cm 2 ). The 5.0% 5FU containing Pheroid solution and the commercial product had the lowest average cumulative concentrations, i.e. 2.58 µg/cm 2 and 2.51 µg/cm 2 , respectively [80] .
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Following the successful outcomes of previous studies [100] on INH (1.0% w/w) and RH (0.5% w/w) (see Section 3.5.3.1), four spray formulations were formulated for these APIs, i.e. a non-Pheroid lotion and emulgel, and a Pheroid lotion and emulgel. Both INH and RH had failed to permeate through full thickness skin (over 12 hours) from all of these formulations. The reason for the inability of the APIs to permeate the skin was believed to have been as a result of the poor release of the APIs from all formulations [126] .
A preliminary study showed that the Pheroid had decreased the flux of ketoconazole (5.0% m/v) across the epidermal layer of human skin, when compared with the control PBS group. The average flux (over 12 hours) of ketoprofen was 0.023 ± 0.010 µg/cm 2 .h and 0.0006 ± 0.0005 µg/cm 2 .h for PBS and the Pheroid, respectively. In addition to the unfavourable physicochemical properties of the API (low aqueous solubility, high molecular weight and a high partition coefficient), this decrease in flux was also ascribed to the crystallisation of the drug within the Pheroid delivery system, which had possibly inhibited the diffusion of ketoconazole through the skin [101] .
Following the initial experiments performed by Kruger [103] to determine the effect of the Pheroid on the transdermal delivery of prilocaine HCl and lidocaine HCl (refer to Section 3.5.3.1), four semi-solid formulations (i.e. a non-Pheroid emulgel, a Pheroid emulgel, a hydrogel and a commercial product) and two solutions (PBS at pH 8, and a solution containing Pheroid) were further tested. The formulations and solutions all contained prilocaine HCl and lidocaine HCl at a concentration of 2.5% w/v. The average flux values after 12 hours (across dermatomed skin, 400 µm) obtained for prilocaine HCl from the various formulations was the highest for the hydrogel (96.490 ± 25.800 μg/cm 2 .h), followed by the commercial product (60. .h). These results indicated that the Pheroid was not superior to the other formulations in enhancing the permeation of these two APIs [96] .
In another study to establish the effectiveness of the Pheroid delivery system, the transdermal penetration of the active ingredient, sodium ascorbyl phosphate (vitamin C) across dermatomed skin was investigated. Different formulations, with varying concentrations of the API (i.e. 1.0, 2.0. and 3.0%), with and without the Pheroid, were examined. Furthermore, a lower polarity, 2.0% sodium ascorbyl phosphate cream, containing more paraffin liquid (with and without Pheroid), and a higher polarity, 2% sodium ascorbyl phosphate cream, containing less paraffin liquid (with and without Pheroid) were investigated. The average intrinsic concentration of vitamin C that had diffused the skin after 12 hours was determined by placing placebo formulations into the donor compartments of the Franz cells. The average placebo effect was then deducted from the results obtained for the vitamin C containing formulations. Results showed that the 2% non-Pheroid cream had the highest average concentration (3.76 μg/cm 2 ) of diffused vitamin C over a period of 12 hours, followed by the 1% nonPheroid formulation (3.56 μg/cm 2 ). It appeared that those formulations with lower concentrations of the API had achieved higher average concentrations than those formulations containing higher amounts of the active. It was also found that the nonPheroid creams had diffused better than their counterpart Pheroid creams, whilst the more polar formulations had penetrated the skin more efficiently than the less polar creams [121] .
A gel, an emulgel and a Pheroid emulgel, each containing ibuprofen (5.0% w/w), were formulated (at pH 5 and pH 7.4) for the purpose of establishing the influence of the Pheroid delivery system, as well as that of pH on the transdermal permeation of the active. A comparison of these results with a commercial product (gel) revealed that all of the formulations had exhibited an increased diffusion of ibuprofen. The emulgel (pH 5) had the highest average cumulative amount of diffused ibuprofen over a 12 hour period, followed by the Pheroid emulgel (pH 5), the gel (pH 5), the emulgel (pH 7.4), the Pheroid emulgel (pH 7.4), the commercial product, and finally the gel (pH 7.4). These results showed that the pH of the formulation had significantly impacted on the permeation of the active [114] .
An anti-inflammatory drug, flurbiprofen (1.0%), was used as a representative compound for investigating the extent to which essential fatty acids (EFAs) would enhance its permeation across dermatomed skin, with and without incorporation into a delivery system. Cream-based formulations, containing evening primrose oil, vitamin F and Pheroid were compared with a control cream. It was found that the evening primrose oil (94.14 ± 25.78 μg/cm 2 ) formulation had resulted in the highest average cumulative concentration of diffused flurbiprofen after 12 hours, followed by the control (91.53 ± 7.24 μg/cm 2 ), and by the vitamin F (81.80 ± 20.15 μg/cm²) and Pheroid (45.32 ± 14.26 μg/cm²) formulations [111] .
Three diclofenac salts (i.e. diclofenac hydroxyethyl pyrrolidine, diclofenac diethylamine and diclofenac sodium, each at 1.0% w/w), none of these possessing favourable physicochemical characteristics for transdermal diffusion, were formulated into Pheroid and non-Pheroid preparations. They were also compared with their corresponding, commercially available counterparts. No diffusion of the diclofenac salts were observed from any of these formulations during the 12 hours of skin diffusion studies [105] .
Cyclizine (5.0%) and scopolamine (1.0%) solutions, each with and without Pheroid, were tested over a period of 12 hours and was found that the cyclizine did not penetrate full thickness skin from any of the preparations, whereas scopolamine did (from both solutions). The scopolamine solution with Pheroid (6.49 μg/cm²) had achieved a lower average cumulative concentration of the API than the solution without Pheroid (14.01 μg.cm²). Following these results, scopolamine was formulated into an emulgel with and without Pheroid. Results from the 12 hours skin diffusion study (using only the epidermis) indicated that the emulgel (2.65 μg/cm²) had generated the highest average concentration of diffused active, compared with the Pheroid emulgel (0.02 μg/cm²) [120] .
Pheroid had not improved the transdermal penetration (through human epidermis) of saturated solutions of zalcitabine, lamivudine and synthesised N-acyl lamivudine esters, when compared to a control group (i.e. actives dissolved in PBS, pH 5). For the PBS (pH 5) solutions it was found that lamivudine (4.289 µmol/cm 2 .h) had resulted in a higher median flux value than zalcitabine (0.442 µmol/cm 2 .h) over 24 hours. Zalcitabine (0.015 µmol/cm 2 .h), however, showed a slightly higher median flux value when entrapped in the Pheroid, than lamivudine (0.011 µmol/cm 2 .h). Lamivudine in PBS (pH 5) and in the Pheroid had a higher median flux value than its derivatives [116] .
Lamivudine and its synthesised methoxypolyethylene glycol carbamates and carbonate (0.2 M) derivatives were also tested using Franz diffusion cells and human epidermis over a period of 24 hours. It was found that the parent drug itself had permeated the skin better than its derivatives in both PBS (pH 7.4) (4.23 ± 2.98 µmol/cm 2 /h) and Pheroid (0.20 ±0.22 µmol/cm 2 /h). Overall, it was found that the Pheroid had inhibited skin permeation, compared with the PBS (pH 7.4) solutions, except for the 2'3'-dideoxy-3'-thiacytidin-6'yl-O-(methoxypolyethylene glycol) carbonate derivative [115] .
Six stavudine-5'-esters were each prepared with and without Pheroid (saturated solutions) and their transdermal penetration investigated. A comparison of the stavudine solutions showed that the average flux values achieved by the PBS (pH 7) solutions over the 24 hours period were slightly higher (6.520 ± 1.402 µmol/cm 2 .h) than those of the Pheroid solutions (6.120 ± 2.857 µmol/cm 2 .h). The flux values of the stavudine PBS (pH 7) solutions were also much higher than those of the PBS (pH 7) solutions containing the stavudine derivatives, ranging between 0.060 and 0.230 µmol/cm 2 .h. Among the Pheroid solutions (ranging between 0.750 and 6.870 µmol/cm 2 .h), however, the butyryl (6.870 ± 3.776 µmol/cm 2 .h) and propionyl esters (6.640 ± 8.429 µmol/cm 2 .h) had achieved the highest fluxes [122] .
The impact of the Pheroid technology was further investigated by formulating and comparing castor oil, vitamin F and Pheroid creams containing tretinoin (0.025% w/w) and adapalene (0.1% w/w). No retinoids were detected in any of the receptor compartments of the Franz cells after 12 hours (with full thickness human abdominal skin) for any of the formulations tested. It was, however, suggested that a low percentage of unionised molecules, the lipophilicity of the retinoids and inadequate concentration gradients had negatively affected the diffusion results. It was also believed that due to the suboptimal release of these actives from the cream formulations, decreased concentrations of retinoids had been available for diffusion (as established through membrane studies) [127] .
Skin diffusion studies (6 hours) were performed on creams and emulgels (with and without Pheroid) containing vitamin A acetate (0.5%) across full thickness abdominal skin. These formulations were compared to a commercial product containing vitamin A acetate. Results indicated that vitamin A acetate had not penetrated through the skin from any of the developed formulations or the commercial product [97] .
The impact of the Pheroid delivery system on the transdermal delivery (across full thickness skin) of niacinamide (3.0%) from cream and emulgel (each with and without Pheroid) formulations was also investigated. The average cumulative concentration of nicotinamide after 12 hours was the highest for the emulgel (29.07 µg/mL), followed by the Pheroid emulgel (23.60 µg/mL). The Pheroid cream (21.41 µg/mL), however, had a higher average cumulative concentration of nicotinamide after 12 hours than its counterpart, i.e. the cream formulation (13.91 µg/mL) [118] .
In another study, a Pheroid gel was compared to a gel formulation without Pheroid, both containing salicylic acid (2.0% w/w) and niacinamide (3.0% w/w). Cream formulations containing salicylic acid at a concentration of 2.0% w/w and niacinamide at a concentration of 4.0% w/w were also compared [117] . It is worth mentioning that the formulations tested during this study differed from the above mentioned study [118] . Full thickness human abdominal skin of Caucasian female patients was used to perform the 12 hours diffusion studies. [117] .
In a further study, different cream and gel formulations, containing niacinamide (4.0%), were formulated with and without Pheroid. Following 12 hours of Franz cell diffusion studies on full thickness female abdominal skin, no flux values were obtained for these formulations. The average cumulative concentration of niacinamide after 12 hours, however, was highest for the cream formulation (65.31 µg/cm 2 ), followed by the Pheroid cream (16.15 µg/cm 2 ), the gel (7.70 µg/cm 2 ) and lastly the Pheroid gel (3.50 µg/cm 2 ) [87] .
These studies with niacinamide showed that the type of formulation could significantly impact the transdermal delivery of an API and requires careful consideration during the formulation process.
Summary and future perspectives
Vesicular carriers have shown high potential as vectors for transdermal drug delivery, due to their versatility, small size, control over drug entrapment and release, and their ability to penetrate the skin to some extent. Many attempts have been made for enhancing transdermal drug delivery by employing classical vesicular systems (liposomes, transfersomes, ethosomes and niosomes), while some studies also reported on the mechanisms of penetration. Much of the available reported test outcomes to date are, however, somewhat speculative, while different research groups have different opinions regarding the mechanism and extent of vesicular penetration into the skin. No general mechanism therefore currently exists that accurately describes the vesicular action, and there are many variables, such as composition and methods of preparation, that result in vesicles with diverse properties in terms of size, shape, charge, fluidity, elasticity and entrapment of APIs.
The Pheroid is a relatively new vesicular delivery system that is very adaptable, effective and cost-effective, and is it composed of pharmaceutically safe constituents, based on the innate molecules in the body [76] . Pheroid, like other vesicular counterparts, are also capable of entrapping, protecting and delivering both hydrophobic and hydrophilic drug molecules across a series of biological membranes [3] , such as human skin.
Ideally, for an API to permeate the skin, it should have a melting point below 200°C and an aqueous solubility of more than 1 mg/mL [128] . The API should also have a log P value between 1 and 3 [129] and should it be small in size, since molecules larger than 500 Dalton would not diffuse through the skin [128, 130] . A comparison of the physicochemical characteristics of all of the APIs tested failed to establish any pattern within the two groups, i.e. APIs undergoing enhanced transdermal permeation with Pheroid (Table 1) and APIs of which their transdermal permeation had been reduced by the Pheroid technology (Table 2) . It is therefore still unclear whether or not an API requires certain physicochemical characteristics in order for the Pheroid to enhance its permeation. It was also observed that the type of formulation significantly impacted the API's transdermal delivery behaviour.
Further studies could be directed towards the short-and long term stability of Pheroid. More efforts should be focused on optimising the Pheroid preparation technique, whilst a need exists for establishing a correlation between the properties of the API and the Pheroid, to assist in designing successful transdermal delivery products. Formulation stability and future investments could be crucial factors for successfully transforming laboratory scale studies into viable commercial products.
